← All indications
Thrombocythemia, Essential
A clinical syndrome characterized by repeated spontaneous hemorrhages and a remarkable increase in the number of circulating platelets.
Drugs by status
Approved for this indication (3)
Phase 4 trials (1)
Phase 3 trials (7)
Phase 2 trials (44)
- decitabine
- azacitidine
- acetylcysteine
- venetoclax
- mirabegron
- busulfan
- lenalidomide
- prednisone
- tacrolimus
- imatinib
- naltrexone
- aldesleukin
- beclomethasone
- Imetelstat
- lestaurtinib
- pd-l1 peptide vaccine
- pevonedistat
- piperine
- zarnestra
- carboplatin
- allogeneic hematopoietic stem cells
- fedratinib
- cyclosporine
- mycophenolate
- sonidegib
- cyclophosphamide
- daunorubicin
- allogeneic lymphocytes
- topotecan
- triapine
- +14 more
Phase 1 trials (17)
Other trials (3)
Organizations
Organization Involved with Phase 4 Indications (4)
Organization Involved with Phase 3 Indications (26)
- Incyte
- Celgene
- Roche
- Gilead Sciences
- AOP Orphan Pharmaceuticals AG
- CTI BioPharma
- Constellation Pharmaceuticals
- EPS Corporation
- Sierra Oncology, Inc.
- National Cancer Institute (NCI)
- University of London
- French Innovative Leukemia Organisation
- Osaka University
- Queen's University, Belfast
- RWTH Aachen University
- University of Southern Denmark
- Mayo Clinic
- Icahn School of Medicine at Mount Sinai
- Medpace, Inc.
- Medical University of Vienna
- University of Texas at Houston
- Myeloproliferative Disorders Research Consoritum
- University of Paris
- Assistance Publique - Hôpitaux de Paris
- Brightech International
- PharmaEssentia Corp.
Organization Involved with Phase 2 Indications (41)
- S*BIO
- Jazz Pharmaceuticals
- YM Biosciences
- Cephalon
- Pfizer
- Sanofi
- Geron Corporation
- Karyopharm Therapeutics Inc
- Promedior, Inc.
- Imago BioSciences
- National Heart, Lung, and Blood Institute (NHLBI)
- Cornell University
- Harvard University
- Eastern Cooperative Oncology Group
- University of Washington
- Johns Hopkins University
- McGill University
- Melbourne Health
- Stanford University
- Swiss Group for Clinical Cancer Research
- Thomas Jefferson University
- University of Miami
- University of Ottawa
- University of South Florida
- University of Toronto
- University of Adelaide
- University of Bern
- University of Chicago
- University of Copenhagen
- University of Utah
- +11 more
Organization Involved with Phase 1 Indications (16)
- AstraZeneca
- Eli Lilly
- Exelixis
- Sponsor GmbH
- Forbius
- University of Pittsburgh
- AIDS Malignancy Consortium
- University of Maryland
- Institut Gustave Roussy
- City of Hope National Medical Center
- State University of New York, Buffalo
- The Leukemia and Lymphoma Society
- Samus Therapeutics
- Center for Cancer Immune Therapy, Denmark
- The University of Texas, Dallas
- Myeloproliferative Neoplasm Research Consortium (MPN-RC)
Organization Involved with Other Experimental Indications (1)